Please ensure Javascript is enabled for purposes of website accessibility

CureVac's Potential Has Wall Street Sending Mixed Signals

By Rich Duprey - Apr 26, 2021 at 12:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech still has a long way to go to prove itself and justify its current stock valuation.

While there seems general acknowledgment that CureVac (CVAC -1.05%) can still win a seat at the COVID-19 vaccine table -- and arguably, take up a lot of room at that table -- Wall Street remains largely unimpressed by the biotech at the moment.

Analysts from both Guggenheim Securities and Credit Suisse (CS -2.28%) weighed in on CureVac Monday, and neither saw its outlook as being especially robust.

Technician testing sample under microscope

Image source: Getty Images.

Guggenheim analyst Seamus Fernandez initiated coverage on CureVac with a neutral rating, but didn't assign a price target to the stock; Credit Suisse's Tiago Fauth began coverage with an underperform rating and a price target of $50, which is some 57% below where the stock closed Friday.

In his note to investors, Fernandez said that it has been less than a year since CureVac went public, and assuming its COVID-19 vaccine is actually effective, the biotech could "evolve from a research driven mRNA company to a fully integrated biopharma vaccine manufacturer and developer" taking a modest amount of market share.

CureVac has developed a messenger RNA (mRNA) COVID-19 vaccine similar to those of Moderna (MRNA 3.73%) and Pfizer (PFE -1.28%) and BioNTech (BNTX 2.24%), but one that has a longer shelf life at standard refrigerator temperatures. It can be stored for up to three months in refrigeration compared to 30 days for Moderna's mRNA-1273, and just five days for Pfizer and BioNTech's BNT162b2.

It's the long-term potential for mRNA vaccines like CureVac's that Fernandez is looking at. He believes they will be the predominant form of protection from the coronavirus. The problem for investors is that one can't accurately assign a value to CureVac. The company's just too early in its lifecycle to make a definitive declaration.

Credit Suisse's Fauth had no such compunctions about putting a number on CureVac, but the investment bank has held dour views on it for some time. In December, Credit Suisse suggested CureVac's vaccine was inferior to its rivals' vaccines, and that the  biotech stock sported a valuation that was much too rich for it to justify.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CureVac N.V. Stock Quote
CureVac N.V.
$14.09 (-1.05%) $0.15
Pfizer Inc. Stock Quote
Pfizer Inc.
$51.64 (-1.28%) $0.67
Credit Suisse Group AG Stock Quote
Credit Suisse Group AG
$5.57 (-2.28%) $0.13
Moderna, Inc. Stock Quote
Moderna, Inc.
$155.54 (3.73%) $5.59
BioNTech SE Stock Quote
BioNTech SE
$161.03 (2.24%) $3.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.